Randomized prospective studies, such as the Keynote 042 trial of first line pembrolizumab versus chemotherapy in PD-L1 > 1% NSCLC, provide further evidence of the clinical effectiveness of ICIs in KRASm patients. Here, CD274 is linked to non-small cell lung carcinoma.